Immix Biopharma Stock Forecast
NASDAQ: IMMXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
Market open · Delayed 15 min · as of Oct 8, 1:02 PM ET
IMMX analyst consensus
Consensus (7 analysts)
strong_buy
Avg. price target
$24.30+162.70%
- Strong buy 3
- Buy 4
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 7 Wall Street analysts covering Immix Biopharma (2026-10-08), 7 rate the stock a buy or strong buy, 0 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "strong_buy". The average 12-month price target is $24.30, with a high estimate of $30.00 and a low estimate of $17.40. The average target implies upside of 162.7% from the current price of $9.25.
The spread between the highest and lowest targets is 72.4%, a relatively narrow range. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for IMMX.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 3 | 43% |
| Buy | 4 | 57% |
| Hold | 0 | 0% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-08.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $17.40 | +88.11% |
| Average target | $24.30 | +162.70% |
| High target | $30.00 | +224.32% |